CRISPR Therapeutics AG (NASDAQ:CRSP) previous close was $112.66 while the outstanding shares total 75.00M. The firm has a beta of 2.29. CRSP’s shares traded lower over the last trading session, losing -1.86% on 05/19/21. The shares fell to a low of $106.75 before closing at $110.56. Intraday shares traded counted 1.13 million, which was 37.95% higher than its 30-day average trading volume of 1.82M. The stock’s Relative Strength Index (RSI) is 44.82, with weekly volatility at 6.33% and ATR at 7.46. The CRSP stock’s 52-week price range has touched low of $58.02 and a $220.20 high.
Investors have identified the Biotechnology company CRISPR Therapeutics AG as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $7.93 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
CRISPR Therapeutics AG (CRSP) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 1.83 billion total, with 83.09 million as their total liabilities.
CRSP were able to record -107.69 million as free cash flow during the 08/11/2021 quarter of the year, this saw their quarterly net cash flow reduce by -42.56 million. In cash movements, the company had a total of -100.66 million as operating cash flow.
Potential earnings growth for CRISPR Therapeutics AG (CRSP)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/11/2021 quarter of the year, CRISPR Therapeutics AG recorded a total of 0.54 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 70.87% coming in sequential stages and their sales for the 08/11/2021 quarter increasing by 31.35%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 0.54 million trying to sell their products during the last quarter, with the result yielding a gross income of 115.08 million. This allows shareholders to hold on to 75.00M with the recently reported earning now reading -1.51 cents per share. This is a figure that compared to analyst’s prediction for their 08/11/2021 (-1.51 cents a share).
Having a look at the company’s valuation, the company is expected to record -6.22 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CRSP sounds very interesting.
Is the stock of CRSP attractive?
In related news, Director, Bolzon Bradley J PhD sold 30,374 shares of the company’s stock in a transaction that recorded on Mar 22. The sale was performed at an average price of 132.37, for a total value of 4,020,667. As the sale deal closes, the Director, Bolzon Bradley J PhD now sold 171,003 shares of the company’s stock, valued at 25,497,840. Also, General Counsel and Secretary, KASINGER JAMES R. sold 27,500 shares of the company’s stock in a deal that was recorded on Jan 19. The shares were price at an average price of 204.94 per share, with a total market value of 5,635,944. Following this completion of acquisition, the Chief Executive Officer, Kulkarni Samarth now holds 20,000 shares of the company’s stock, valued at 4,273,311. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.20%.
14 out of 21 analysts covering the stock have rated it a Buy, while 5 have maintained a Hold recommendation on CRISPR Therapeutics AG. 2 analysts has assigned a Sell rating on the CRSP stock. The 12-month mean consensus price target for the company’s shares has been set at $160.00.